CXCR2 and ovarian serous cystadenocarcinoma: However, in esophageal carcinoma, ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, and breast invasive carcinoma, more than 2% of cases had amplifications of CXCR2 ligand genes (Table 20).